Common Stock, par value $0.0001
- Symbol
- NTHI
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 7.01, 9.01 · 8-K
NeOnc Technologies Holdings, Inc.
NTHINASDAQEQUITYCurrent
Results of Operations and Financial Condition · Regulation FD Disclosure
Item Results 2.02. of Operations and Financial Condition. On August 10, 2026, NeOnc Technologies Holdings, Inc. (the “Company”) issued a press release reporting second quarter financial results and confirmed that topline results from its fully enrolled Phase 2a NEO100 study will be presented on August 12, 2026.…
Company context
Our company (f/k/a NAS-ONC, Inc.) was formed in 2008, devoted to developing new drugs with new delivery modes. As a clinical-stage biopharmaceutical company, we have focused on establishing treatments for intracranial malignancies, i.e., aggressive cancers located in the brain. These cancer types include primary brain cancers, such as glioblastoma, and secondary brain cancers, that have arrived through metastatic spread from other cancers throughout the body, such as melanoma or breast and lung cancer. Brain-localized malignancies are particularly difficult to treat because the blood-brain barrier prevents efficient entry of most pharmacotherapeutic agents into the brain. As a result, these patients are faced with poor prognoses and shortened average life expectancy. NeOnc is developing novel drug delivery methods to be used in combination with novel drug candidates.
Current securities
Recent company filings
- Regulation FD DisclosureOct 22, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureOct 15, 2026
- Regulation FD DisclosureSep 28, 2026
- Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Regulation FD DisclosureSep 21, 2026
- Regulation FD DisclosureSep 17, 2026
Registered securities in this filing
NEONC TECHNOLOGIES HOLDINGS, INC. · 8-K · Filed 2026-08-10
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item Results
2.02. of Operations and Financial Condition.
On
August 10, 2026, NeOnc Technologies Holdings, Inc. (the “Company”) issued a press release reporting second quarter financial
results and confirmed that topline results from its fully enrolled Phase 2a NEO100 study will be presented on August 12, 2026. A copy
of the press release is attached hereto as Exhibit 99.1 and the information therein is incorporated herein by reference.
The
information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the
Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), except as shall be expressly set forth by
specific reference in such filing.
Item 7.01Item 7.01 - Regulation FD Disclosure
Item Regulation
7.01. FD Disclosure.
The
information under Item 2.02, above, is incorporated herein by reference.
On August 10, 2026, the Company issued a press release announcing that
it will host an investor conference call and webcast on Wednesday, August 12, 2026, at 8:30 a.m. Eastern Time to present results
from the Phase 2a portion of the NEO100-01 clinical trial. A copy of the press release is furnished as Exhibit 99.2 to this Current Report
on Form 8-K.
The information reported under Items 2.02 and
7.01 in this Current Report on Form 8-K, including Exhibit 99.1 and Exhibit 99.2 attached hereto, shall not be deemed filed for purposes
of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference
in any filing under the Securities Act or the Exchange Act, regardless of any general incorporation language in such filing.
Filed exhibits (2)
EX-99.1 2 neonctechnologies_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 NeOnc Reports Second Quarter 2026 Financial Results and Confirms August 12 Topline Phase 2a NEO100 Data Readout CALABASAS, Calif., Aug. 10, 2026 -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments for central nervous system cancers, today announced financial results for the second quarter ended June 30, 2026, highlighted recent clinical and regulatory progress across its NEO100 and NEO212 programs, and confirmed that topline results from its fully enrolled Phase 2a NEO100 study will be presented on August 12, 2026. Amir Heshmatpour, Executive Chairman, President and Chief Executive Officer, commented: “The second quarter positioned NeOnc for an important period of clinical execution. We completed the topline analysis of our fully enrolled Phase 2a NEO100 study in recurrent IDH1-mutant high-grade glioma and look forward to presenting the results to investors on August 12. This is one of the most important clinical milestones in NeOnc’s history. “At the same time, we secured UAE IND approvals for both NEO100 …
Open exhibit ↗EX-99.2 3 neonctechnologies_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 NeOnc Technologies to Host Investor Conference Call to Discuss Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma Call to be held Wednesday, August 12, 2026 at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time CALABASAS, Calif., Aug. 10, 2026 - NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that it will host an investor conference call and webcast on Wednesday, August 12, 2026, at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. During the call, members of the NeOnc management team will present topline results from the Phase 2a portion of the NEO100-01 clinical trial, an open-label study of intranasal NEO100™, the Company’s proprietary formulation of purified perillyl alcohol, in patients with recurrent or progressive Grade III and Grade IV IDH1-mutant glioma. The discussion will include efficacy and safety observations from the Phase 2a portion of the NEO100-01 clinical trial and planned regulatory next…
Open exhibit ↗